Nanoparticles for dual-targeted treatment of breast cancer as well as preparation method and application of nanoparticles

Through the amphiphilic conjugate of Dendrobium officinale and cholesterol hemisuccinate amphiphilic conjugate combined with folic acid ligand, dual-targeted treatment for breast cancer is achieved, solving the problems of low toxicity and targeting efficiency of chemotherapy drugs, and significantly improving the The therapeutic effect and immune response.

CN118903468AActive Publication Date: 2024-11-08THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411107374.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-08
Estimated Expiration
2044-08-13

AI Technical Summary

Technical Problem

Among the existing breast cancer treatment methods, chemotherapy drugs such as doxorubicin are cardiotoxic, and the targeting efficiency of nanoparticles to breast cancer sites is not high, and it cannot effectively inhibit tumor growth and metastasis.

Method used

Dendrobium officinale polysaccharide-cholesterol hemisuccinate amphiphilic conjugate is used as a drug carrier, combining with folic acid ligands to achieve the dual targeting function of nanoparticles, and improve the transmission efficiency and immune enhancement of chemotherapy drugs through passive and active targeting mechanisms. Effect.

Benefits of technology

It significantly improves the inhibitory rate of breast cancer and the inhibitory effect of lung metastasis, reduces the toxicity of chemotherapy drugs, enhances the activity of immunogenic cells, simplifies treatment strategies, and avoids the need for additional immune adjuvants.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903468A_ABST
    Figure CN118903468A_ABST
Patent Text Reader

Abstract

The invention discloses a nanoparticle for dual targeted treatment of breast cancer as well as a preparation method and application of the nanoparticle. According to the nanoparticles for dual targeting treatment of breast cancer, a dendrobium officinale polysaccharide-cholesterol hemisuccinate amphiphilic conjugate is used as a drug carrier to entrap an anti-breast cancer chemotherapy drug, and the surface of the drug carrier is modified with a folic acid ligand. According to the invention, the dendrobium officinale polysaccharide with immunoregulatory activity is used as a carrier, and is combined with the folic acid ligand with an active targeting function, so that dual targeting of breast cancer is realized, and the effect of chemotherapy and immunotherapy is exerted. After the prepared nanoparticles are delivered to a solid tumor in a passive and active targeting manner, tumor cells are killed by a released chemotherapeutic drug (adriamycin), immunogenic cell death (ICD) is enhanced through the dendrobium officinale polysaccharide, proliferation of natural killer cells (NK cells) is promoted, dendritic cells are stimulated to be mature, various immune cells are synergistically regulated, and the curative effect is improved. Meanwhile, lung metastasis of breast cancer is prevented.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and more specifically, to a nanoparticle for dual-targeted treatment of breast cancer, and a preparation method and application thereof. Background Art

[0002] Breast cancer has become the most commonly diagnosed cancer among women worldwide and ranks fifth in cancer-related deaths. The high mortality rate of breast cancer is mainly attributed to tumor metastasis, with distant metastasis accounting for more than 90% of breast cancer-related deaths. Therefore, there is an urgent need to design novel therapeutic strategies to prevent the growth and metastasis of breast cancer. In current clinical practice, chemotherapy drugs, such as doxorubicin (Dox), represent a commonly used cancer treatment method. However, doxorubicin treatment can exhibit significant cardiotoxicity. Fortunately, previous studies have shown that the use of nanoparticle encapsulation can significantly reduce doxorubicin-related toxicity. However, based solely on the EPR effect of nanoparticles (passive targeting strategy), the efficiency of nanoparticles enriching breast cancer sites is not high.

[0003] Nanoparticles can reach tumors through both passive and active targeting processes. Passive tumor targeting exploits enhanced penetration and retention, resulting in prolonged circulation of nanoparticles within the tumor. Active targeting typically involves modifying nanoparticle carriers with molecules or antibodies that are highly selective and specific for tumors. This active targeting approach holds great potential for directing drug nanocarriers to tumor tissue.

[0004] Zhang G et al. disclosed a pH-responsive micelle based on folate-modified Bletilla striata polysaccharide loaded with doxorubicin (Zhang G, Huang L, Wu J, et al. Doxorubicin-loaded folate-mediated pH-responsive micelle based on Bletilla striata polysaccharide: Release mechanism, cellular uptake mechanism, distribution, pharmacokinetics, and antitumor effects - Science Direct [J]. International Journal of Biological Macromolecules, 2020, 164: 566-577. DOI: 10.1016 / j.ijbiomac.2020.07.123.) Specifically disclosed is the coupling of the hydrophobic group stearic acid (SA) and the targeting group folic acid (FA) on the hydroxyl group of Bletilla striata polysaccharide through an ester bond, and the preparation of a folic acid receptor-targeted (FA-BSPs-SA) derivative based on stearic acid-modified Bletilla striata polysaccharide (BSPs-SA). A complex of doxorubicin hydrochloride and sodium cholate was prepared through electrostatic interaction and directly encapsulated into FA-BSP-SA micelles. FA-BSP-SA micelles increased the absolute bioavailability of Dox (p < 0.01) and prolonged the average residence time. However, the biocompatibility of the stearic acid used is relatively low, which may trigger certain biological reactions, and its inhibition rate on tumors needs to be improved and it does not have the function of preventing and treating breast cancer lung metastasis. Summary of the Invention

[0005] The purpose of the present invention is to overcome the above-mentioned defects and deficiencies in the prior art and to provide a nanoparticle for dual-targeted treatment of breast cancer.

[0006] The second object of the present invention is to provide a method for preparing the dual-targeted nanoparticles for treating breast cancer.

[0007] The third object of the present invention is to provide the application of the dual-targeted nanoparticles for treating breast cancer.

[0008] The above-mentioned object of the present invention is achieved through the following technical solutions:

[0009] A dual-targeted nanoparticle for breast cancer therapy uses a Dendrobium officinale polysaccharide-cholesterol hemisuccinate amphiphilic conjugate (CHS-DOP) as a drug carrier to encapsulate an anti-breast cancer chemotherapy drug. The drug carrier is surface-modified with a folic acid (FA) ligand. It exhibits both passive and active targeting capabilities. The structural formula of the Dendrobium officinale polysaccharide-cholesterol hemisuccinate amphiphilic conjugate is shown below:

[0010] n is 1 to 2.

[0011] Dendrobium officinale is a traditional Chinese medicine with the effects of nourishing yin, clearing heat, and promoting stomach function. It has been used as a traditional Chinese medicine and in therapeutic food products (such as soups) for thousands of years. In recent years, Dendrobium officinale has been listed by the National Health Commission of China as a "medicine and food of the same origin," indicating its safety and non-toxicity. Among its key components, polysaccharides play an important role in disease treatment. Prior art has demonstrated that polysaccharides have anti-cancer activity. Due to their excellent biocompatibility, lack of side effects, and ease of modification, polysaccharides are widely used as nanocarriers. As carriers, Dendrobium officinale polysaccharides offer advantages such as being naturally pollution-free, biocompatible, degradable through normal metabolic pathways, and possessing immunogenic activity. Furthermore, Dendrobium officinale polysaccharides possess anti-tumor properties and can stimulate the maturation of dendritic cells, further enhancing the efficacy of chemotherapy drugs. Folate receptors (FRs) are a type of cell surface receptor that play a role in transporting folic acid into cells. FRs have been observed to be overexpressed in various tumor cells, including ovarian cancer, triple-negative breast cancer, endometrial cancer, mesothelioma, colon cancer, and lung cancer, while their expression in normal cells is minimal. Specific cell targeting can be achieved by conjugating nanocarriers with ligands targeting FRs. Previous studies have also demonstrated enhanced accumulation of FA-targeted drug delivery vehicles in tumor models expressing FRs. Therefore, surface modification with FA ligands and an active targeting strategy could enhance the delivery efficiency of nanomedicines to target tumor tissues.

[0012] The present invention utilizes Dendrobium officinale polysaccharide as a drug transport carrier to enhance anti-tumor effect. The structure of Dendrobium officinale polysaccharide (DOP) is mainly composed of mannose and glucose. Utilizing the favorable properties of Dendrobium officinale, it is used as a hydrophilic group, and cholesterol hemisuccinate (CHS) is used as a hydrophobic group. The formed Dendrobium officinale polysaccharide-cholesterol hemisuccinate (CHS-DOP) amphiphilic conjugate can be loaded with hydrophobic chemotherapy drugs and has passive targeting function. Since cholesterol hemisuccinate is a natural component in the human body, cholesterol hemisuccinate has good biocompatibility in biological systems, reducing potential toxicity and side effects. It is then modified with folic acid ligands to give it an active targeting function, thereby exerting a dual targeting function. More nanoparticles are transported into breast cancer cells by FA, ​​so that the effect of chemotherapy drugs on chemotherapy immunity enhancement is further greatly enhanced. The nanoparticles for the dual-targeted treatment of breast cancer have significant efficacy, which can not only inhibit breast tumor growth, but also inhibit breast tumor lung metastasis.

[0013] Furthermore, the nanoparticles are uniform in size, with a particle diameter of 210 to 220 nm and a Zeta potential of -11 to -14 mV.

[0014] Furthermore, the anti-breast cancer chemotherapy drug is doxorubicin (Dox).

[0015] Furthermore, the Dendrobium officinale polysaccharide has a main chain of (1→4)-linked β-pyranose and β-D-pyranose glucose, and a side chain consisting of terminal pyranose, composed of mannose and glucose in a ratio of 4.47:1, with an average molecular weight of 80.32 kDa; the CHS-DOP is modified with one CHS unit for every seven monosaccharide units. It can be prepared according to the existing technology (Tao S, Song Y, Ding S, et al. Dendrobium officinale polysaccharide-based carrier to enhance photodynamic immunotherapy. [J]. Carbohydrate polymers, 2023, 317:, 121089. DOI: 10.1016 / j.carbpol.2023.121089.).

[0016] The present invention also provides a method for preparing any of the aforementioned dual-targeted nanoparticles for treating breast cancer, comprising the following steps:

[0017] S1. Dendrobium officinale polysaccharide was reacted with cholesterol hemisuccinate in the presence of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) to link the hydroxyl groups of the Dendrobium officinale polysaccharide with the carboxyl groups of cholesterol hemisuccinate to form a Dendrobium officinale polysaccharide-cholesterol hemisuccinate amphiphilic conjugate (CHS-DOP conjugate).

[0018] S2. The Dendrobium officinale polysaccharide-cholesterol hemisuccinate amphiphilic conjugate prepared in step S1 was subjected to a coupling reaction with folic acid in an organic solvent under the action of EDC·HCl and 4-dimethylaminopyridine (DMAP), followed by dialysis and alcohol precipitation to prepare a folic acid-conjugated Dendrobium officinale polysaccharide-cholesterol hemisuccinate conjugate (FA-DOP-CHS);

[0019] S3. Dissolving the anti-breast cancer chemotherapy drug and the folic acid-conjugated Dendrobium officinale polysaccharide-cholesterol hemisuccinate conjugate described in step S2 in an organic solvent, reacting, dialysis, centrifugation, and filtration to obtain nanoparticles encapsulating the anti-breast cancer chemotherapy drug.

[0020] Furthermore, in step S1, the mass ratio of Dendrobium officinale polysaccharide to cholesterol hemisuccinate is 1.6-1.7:1.

[0021] Furthermore, in step S2, the mass ratio of the Dendrobium officinale polysaccharide-cholesterol hemisuccinate amphiphilic conjugate to folic acid is 2.2-2.3:1.

[0022] Preferably, the organic solvent in steps S2 and S3 is dimethyl sulfoxide (DMSO).

[0023] Furthermore, the weight ratio of the anti-breast cancer chemotherapy drug to the folic acid-conjugated Dendrobium officinale polysaccharide-cholesterol hemisuccinate conjugate is 1:4-6.

[0024] Preferably, the weight ratio of the anti-breast cancer chemotherapy drug to the folic acid-conjugated Dendrobium officinale polysaccharide-cholesterol hemisuccinate conjugate is 1:5.

[0025] Furthermore, the dialysis in step S2 is performed using a dialysis bag with a molecular weight cutoff value of 3500 Da.

[0026] Furthermore, the dialysis in step S3 is performed using a dialysis bag with a molecular weight cutoff value of 5000 Da.

[0027] Furthermore, the filtration in step S3 is performed by using a 0.45 μm microporous membrane.

[0028] Preferably, the preparation method of the Dendrobium officinale polysaccharide comprises ethanol precipitation of the hot water-extracted Dendrobium officinale extract, followed by oxidative degradation with H2O2 and FeCl2·4H2O, and then freeze-drying to obtain Dendrobium officinale polysaccharide (DOP). The purity of DOP is 84.82%. DOP is composed of mannose and glucose in a ratio of 4.47:1 and has an average molecular weight of 80.32 kDa.

[0029] The present invention utilizes the favorable properties of DOP, using it as a hydrophilic group and cholesterol hemisuccinate (CHS) as a hydrophobic group to form an amphiphilic conjugate called CHS-DOP. Subsequently, a FA-conjugated lipid, FA-DOP-CHS, was synthesized. A Dox-containing carrier was prepared, and FA-DOP-CHS@Dox (abbreviated as "FA@Dox" nanoparticles (NPs) were prepared. Various characterizations were then carried out, including drug loading capacity, critical micelle concentration (CMC), drug release, cellular uptake efficiency, and cytotoxicity evaluation against FR-rich cancer cells (4T1 and CT26 cells) and FR-poor normal cells (L929 cells). Next, in vivo imaging experiments were performed and FA@Dox was evaluated in the 4T1 mouse model. The anti-tumor and anti-metastasis effects of NPs were studied to evaluate the therapeutic effect. In addition, a biosafety assessment was performed, and the immune responses in vivo and in vitro were analyzed. The results showed that after the obtained FA@Dox nanoparticles were delivered to solid tumors through passive and active targeting, the tumor cells were killed by the released doxorubicin, and DOP enhanced immunogenic cell death (ICD), promoted the proliferation of natural killer cells (NK cells), promoted the maturation of dendritic cells, and synergistically regulated various immune cells, while preventing breast cancer lung metastasis. In summary, the present invention prepares a breast cancer targeted preparation with dual targeted therapy for breast cancer to treat breast cancer occurrence and lung metastasis.

[0030] Therefore, the present invention also provides the use of any of the above-mentioned dual-targeted nanoparticles for treating breast cancer in the preparation of a pharmaceutical preparation for treating breast cancer.

[0031] The present invention also provides the use of any of the above-mentioned dual-targeted nanoparticles for treating breast cancer in the preparation of a pharmaceutical preparation for preventing and / or treating lung metastasis of breast cancer.

[0032] The present invention also provides a pharmaceutical preparation for treating breast cancer, which contains any of the above-mentioned dual-targeted nanoparticles for treating breast cancer.

[0033] Furthermore, the medicine also includes pharmaceutically acceptable excipients.

[0034] Compared to Zhang's study, the present invention offers the following advantages: ① Because cholesterol hemisuccinate is a natural component in the human body, it exhibits excellent biocompatibility in biological systems, reducing potential toxicity and side effects. The main advantages of cholesterol hemisuccinate over stearic acid are its excellent biocompatibility, high chemical activity, versatile structural rigidity, and tunable hydrophobicity. The nanoparticles prepared in this invention exhibit excellent biocompatibility, no toxic side effects, and good blood compatibility. ② The tumor inhibition rate of the FA@Dox nanoparticles prepared in this invention is 1.4 times that of free Dox, exceeding the 1.38-fold rate reported in Zhang's paper. ③ The FA@Dox nanoparticles prepared in this invention can prevent and treat breast cancer metastasis, achieving a 54% inhibition rate for lung metastasis, whereas the nanoparticles prepared in Zhang's paper do not exhibit this effect. ④ As a product listed in the "Medicine and Food" catalog, Dendrobium officinale polysaccharides have anti-tumor and immune-enhancing properties. The content of polysaccharides in Dendrobium officinale is rich. The 2020 edition of the Chinese Pharmacopoeia stipulates that the content of polysaccharides in Dendrobium officinale exceeds 25%, while the content of polysaccharides in Bletilla striata (also known as Bletilla striata) stipulated in the Chinese Pharmacopoeia is 1,4-di[4-(glucose oxygen) benzyl]-2-isobutyl malate (C 34 H 40 O 17 ) must not be less than 1.5%, and is not a polysaccharide. Furthermore, literature reports show that the polysaccharide content of Anlong Bletilla striata is the highest, reaching 23.20%; the lowest is Shibing Bletilla striata, at only 11.70% (Han Xue, Zeng Qinghong, Niu Minmin, et al., Determination of polysaccharide content of fresh Bletilla striata from different origins [J], 2020, 37(12): 34-35.). Compared with Bletilla striata polysaccharides, Dendrobium officinale polysaccharides have greater industrialization potential.

[0035] Compared with the prior art, the present invention has the following beneficial effects:

[0036] The nanoparticles for the dual-targeted treatment of breast cancer of the present invention are based on the amphiphilic conjugate of Dendrobium officinale polysaccharide-cholesterol hemisuccinate as a drug carrier for encapsulating anti-breast cancer chemotherapy drugs, and the surface of the drug carrier is modified with a folic acid ligand. The present invention realizes dual-targeted breast cancer by utilizing DOP with anti-tumor effect and immunomodulatory activity as a carrier, and combines a folic acid ligand with an active targeting function, and exerts the effect of chemotherapy immunotherapy. The nanoparticles prepared at the same time have good biocompatibility, no toxic side effects, and good blood compatibility. After the obtained FA-DOP-CHS@Dox ("FA@Dox") nanoparticles are delivered to solid tumors by passive and active targeting, the tumor cells are killed by the released doxorubicin, and immunogenic cell death (ICD) is enhanced by DOP, the proliferation of natural killer cells (NK cells) is promoted, dendritic cell maturation is further stimulated, and various immune cells are synergistically regulated to exert anti-tumor effects while preventing breast cancer lung metastasis. Compared with chemotherapy alone, the nanoparticles of the present invention have the effect of reducing toxicity and increasing efficacy; compared with the combined treatment strategy of chemotherapy and immunotherapy, the nanoparticles of the present invention do not require the addition of additional immune adjuvants or immune checkpoint inhibitors, which is simpler. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 The characterization results are shown in Figure 2. (A) FT-IR spectra of FA, CHS-DOP and FA-DOP-CHS; (B) FT-IR spectra of CHS, DOP, CHS-DOP, FA and FA-DOP-CHS. 1 H-NMR spectrum; (C) Particle size distribution and morphology of FA@Dox NPs detected by DLS and TEM; (D) Zeta potential of CHS@Dox NPs and FA@Dox NPs; (E) Release curves of Dox from CHS@Dox NPs and FA@Dox NPs at pH 5.5 and 7.4.

[0038] Figure 2 The critical micelle concentration (CMC) of CHS-DOP (A) and FA-DOP-CHS (B) nanoparticles was determined by DLS method and presented as a graph showing the change of particle count rate with concentration.

[0039] Figure 3 is the standard curve of doxorubicin (Dox), which is used to calculate the loading amount and loading rate of Dox in CHS@Dox nanoparticles and FA@Dox nanoparticles.

[0040] Figure 4 The hydrated particle size distribution and morphology of CHS@Dox nanoparticles were detected by dynamic light scattering (DLS) and transmission electron microscopy (TEM), respectively.

[0041] Figure 5Figure 2 shows the particle size changes of CHS@Dox nanoparticles and FA@Dox nanoparticles within 5 days.

[0042] Figure 6 Figure 2 shows the changes in polydispersity index (PDI) of CHS@Dox nanoparticles and FA@Dox nanoparticles within 5 days.

[0043] Figure 7 Confocal images of the cellular uptake of Dox, CHS@Dox, and FA@Dox NPs by 4T1, CT26, and L929 cells. FA / FA@Dox represents FA@Dox NPs pretreated with free FA. Scale bar represents 20 μm.

[0044] Figure 8 Cell viability of (A) 4T1 cells, (B) CT-26 cells, and (C) L929 cells after treatment with free Dox, CHS@Dox nanoparticles, and FA@Dox nanoparticles for 48 h, respectively.

[0045] Figure 9 Evaluation of ICD: (A) CRT exposure and (B) HMGB1 release in 4T1 cells or CT-26 cells treated with different methods under CLSM. Scale bar: 20 μm; (C) ATP secretion in 4T1 cells and CT-26 cells treated with different methods. * P<0.05, ** P<0.01, *** P < 0.001 indicates a significant difference between the treatment group and the control group; ## P<0.01 indicated a significant difference between the FA@Dox group and the free Dox or CHS@Dox group.

[0046] Figure 10 In vivo fluorescence imaging of 4T1 tumor-bearing mice: (A) In vivo fluorescence images at different time points after intravenous injection (the dotted yellow line indicates the tumor location); (B) Fluorescence imaging of organs and tumor tissues in vivo 24 hours after intravenous injection; (C) Quantitative analysis of the mean fluorescence intensity of tumor tissues at different time points (n=3); (D) Quantitative analysis of the mean fluorescence intensity of different organ regions (n=3). * P<0.05, ** P<0.01, *** P < 0.001 represents a significant difference between the treatment group and the free Dir group; # P<0.05 indicates a significant difference between the FA@Dox group and the CHS@Dox group.

[0047] Figure 11Results of in vivo anti-tumor studies. (A) Schematic diagram of breast cancer model construction; (BC) Tumor volume growth curve and representative images; (D) Tumor weight; (H) Mouse body weight; ** P<0.01, *** P < 0.001, treatment group versus control group; # P<0.05, ### P < 0.001, FA@Dox group compared with free Dox group and CHS@Dox group.

[0048] Figure 12 Representative images of H&E staining, Ki67, and TUNEL immunofluorescence of 4T1 tumor sections in different drug-treated groups.

[0049] Figure 13 Representative images of tumor metastasis in the lung tissue of 4T1 lung metastasis model mice (black circles: tumor nodules).

[0050] Figure 14 Results of the anti-metastatic efficacy assay. (A) Schematic diagram of the breast cancer lung metastasis model. (B) Representative photographs showing the appearance of lung metastatic tumor nodules after fixation with Bouin's solution (top, front; bottom, back). (C) Analysis of the average number of lung tumor nodules in different treatment groups. (D) Analysis of lung weight after treatment. * P < 0.05, and ** P < 0.01. (E) Representative histological examination of the entire lung lobe in each group, as measured by H&E staining. Black arrows indicate visible lesions in the lungs. Scale bar = 1.0 mm. (F) Magnified view of the above image. Scale bar = 100 μm.

[0051] Figure 15 Fluorescence imaging of calmodulin exposure (CRT) and high-mobility group protein B1 (HMGB1) release in lung and tumor tissues. Scale bar: 20 μm.

[0052] Figure 16 Results of immune response analysis. Among them, activated DCs (CD80 + CD86 + ) flow cytometric analysis; (C) flow cytometric analysis of CD8 + T cells and CD4 + T cell infiltration; (D) Tregs cells in tumors (CD25 + Foxp3 + T cells); (E) splenic NK cells (CD3 - CD49 + ) flow cytometry analysis; (F) perforin (CD8+ Perforin + ) flow cytometry analysis; (G) determination of granzyme B in the supernatant by ELISA. * P<0.05, ** P < 0.01, *** P<0.001.

[0053] Figure 17 Flow cytometry analysis of mature dendritic cells (CD80 + CD86 + ) ratio.

[0054] Figure 18 Flow cytometry was used to analyze the expression of mature dendritic cells (CD80 + CD86 + ) ratio.

[0055] Figure 19 Flow cytometry analysis of CD8 + T cells and CD4 + The proportion of T cells.

[0056] Figure 20 (A) CD4 + (B) CD8 + and (C)Foxp 3 + cell.

[0057] Figure 21 (A) CD4 + and (B) CD8 + cell.

[0058] Figure 22 Flow cytometry analysis of regulatory T cells (CD25 + Foxp3 + ) ratio.

[0059] Figure 23 Flow cytometry was used to analyze the natural killer cells (CD3 - CD49 + ) ratio.

[0060] Figure 24 Flow cytometry analysis of perforin (CD8 + Perforin + ) The proportion of positive cells.

[0061] Figure 25 Hemocompatibility evaluation results of the nanoparticles. (A) Hemolysis images and (B) hemolysis rates of CHS@Dox and FA@Dox with 2% Triton X-100 as a positive control and PBS buffer as a negative control (n=3) at 37°C for 2 h at different concentrations of NPs ranging from 12.5 to 50 μg / mL.

[0062] Figure 26 Representative images of H&E-stained sections of liver, heart, spleen, lung, and kidney (black arrows: necrotic cardiomyocytes and myocardial fiber fragmentation).

[0063] Figure 27 From left to right, magnified images of H&E-stained cardiac sections from the control and FA@Dox groups are shown. (Black arrows: necrotic cardiomyocytes and myocardial fiber fragmentation).

[0064] Figure 28 Blood biochemical analysis of mice treated with free Dox, CHS@Dox NPs, and FA@Dox NPs.

[0065] Figure 29 Schematic diagram of the FA@DOP nanoparticles of the present invention enhancing chemoimmunotherapy and inhibiting breast cancer growth and lung metastasis. DETAILED DESCRIPTION

[0066] The present invention will be further described below with reference to the accompanying drawings and specific examples, but the examples do not limit the present invention in any way. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0067] Unless otherwise specified, the reagents and materials used in the following examples were commercially available.

[0068] Mouse breast tumor cells (4T1), mouse colon cancer cells (CT-26), and mouse fibroblasts (L929) were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM (Gibco, California, USA) containing 10% FBS and 1% penicillin / streptomycin at 37°C and 5% CO2.

[0069] Example 1 Preparation and characterization of CHS@Dox and FA@Dox

[0070] 1. Method

[0071] (1) Preparation of amphoteric polysaccharides

[0072] Based on the inventors' previous study (Tao S, Song Y, Ding S, et al. Dendrobium officinale polysaccharide-based carrier to enhance photodynamic immunotherapy. [J]. Carbohydrate polymers, 2023, 317:, 121089. DOI: 10.1016 / j.carbpol.2023.121089.), Dendrobium officinale polysaccharide (DOP) and amphoteric CHS-DOP conjugates were prepared. Briefly, the Dendrobium officinale extract after hot water extraction was precipitated with ethanol, followed by oxidative degradation with H2O2 and FeCl2·4H2O. Then, Dendrobium officinale polysaccharide (DOP) was obtained by freeze-drying. The purity of DOP was 84.82%. DOP has a main chain of (1→4)-linked β-pyranose and β-D-pyranose glucose, and a side chain composed of terminal pyranose. DOP is composed of mannose and glucose in a ratio of 4.47:1, with an average molecular weight of 80.32 kDa. DOP is highly water-soluble. To impart its ability to self-assemble in water, the biocompatible hydrophobic moiety, cholesterol hemisuccinate (CHS), was introduced by linking the carboxyl group of CHS to the hydroxyl group of DOP in the presence of EDC·HCl. The synthetic route for the CHS-DOP conjugate is as follows:

[0073]

[0074] n is 1-2; specifically, 121.68 mg of cholesterol hemisuccinate (CHEMS, CHS), 57.5 mg of EDC·HCl (1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride), 36.65 mg of dimethylaminopyridine (DMAP), and 200 mg of DOP were added to 10 mL of dimethyl sulfoxide (DMSO). The reaction product was maintained at 38°C for 48 hours. Cold anhydrous ethanol was added to obtain a precipitate. After filtration and washing with cold anhydrous ethanol, the CHS-DOP conjugate was obtained.

[0075] (2) Synthesis of FA-conjugated CHS-DOP (FA-DOP-CHS)

[0076] CHS-DOP (100.2 mg), EDC·HCl (92.3 mg), DMAP (48.8 mg) and FA (44.1 mg) were added to 4 mL of DMSO and then reacted at 38°C for 48 hours. After the reaction, the mixture was dialyzed for 48 hours using a dialysis bag (molecular weight cutoff value of 3500 Da) in deionized water. Subsequently, the solution was collected and precipitated with cold anhydrous ethanol. The precipitate of FA-DOP-CHS polymer was then freeze-dried and analyzed by FT-IR spectroscopy using a NicoletTM iS50 Fourier transform infrared spectrometer (Thermo Fischer Scientific, Waltham, MA, USA) and a 400 MHz nuclear magnetic resonance spectrometer (AVIII, Bruker, Germany). 1 H NMR ( 1 H NMR) spectral characterization.

[0077] (3) Preparation of CHS@Dox and FA@Dox nanoparticles

[0078] Doxorubicin (Dox), CHS-DOP or FA-DOP-CHS were dissolved in DMSO, respectively. The doxorubicin solution was then added dropwise to the CHS-DOP or FA-DOP-CHS solution, stirred at room temperature and maintained for 2 hours (doxorubicin / CHS-DOP or FA-DOP-CHS weight ratio was 1:5). The solution was then transferred to a dialysis bag (molecular weight cutoff of 5000 Da) in deionized water for 24 hours to remove unloaded drugs and DMSO. Finally, the resulting solution was centrifuged at 3000 rpm for 5 minutes and filtered through a 0.45 μm microporous membrane to obtain CHS-DOP@Dox (abbreviated as 'CHS@Dox') or FA-DOP-CHS@Dox (abbreviated as "FA@Dox") NPs.

[0079] (4) Critical micelle concentration (CMC)

[0080] The CMC of CHS-DOP and FA-DOP-CHS was determined using dynamic light scattering (DLS). Briefly, CHS-DOP or FA-DOP-CHS was serially diluted with water to concentrations of 0.001, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, and 10 μg / mL. Changes in particle count rate due to micelle formation were measured using a NanoBrook 90Plus Zeta (Brookhaven Instruments Corporation, New York, USA). The CMC was determined as the concentration at the inflection point of the DLS data curve.

[0081] (5) Nanoparticle characterization

[0082] The particle size and polydispersity index (PDI) of CHS@Dox and FA@Dox were measured using a NanoBrook 90Plus Zeta. Subsequently, the zeta potential was determined using a Nano-ZS90 ZetaSizer (Malvern Panalytical Ltd., UK). The morphology of DOP@3BCP and PEG@3BCP was observed using a JEM-2100 transmission electron microscope (TEM) (JEOL, Tokyo, Japan). The Dox content was determined by fluorescence measurement (excitation wavelength 480 nm) in the dark using a standard curve. The drug loading content (DLC) and drug loading efficiency (DLE) were calculated from the obtained data.

[0083] (6) In vitro Dox release curve

[0084] The Dox release profiles of CHS@Dox or FA@Dox NPs were determined using a dialysis method. Briefly, CHS@Dox or FA@Dox (300 μg Dox content) was encapsulated in a dialysis bag with a molecular weight cutoff of 3500 Da and immersed in a PBS solution (15 mL, pH = 5.5 or 7.4) and then placed in a shaker at 37°C. Finally, 1 mL of the PBS solution was regularly replaced with the same volume of fresh PBS to maintain the same volume. The Dox content in the sample was determined by fluorescence measurement.

[0085] 2. Results

[0086] (1) Characterization of DOP and CHS-DOP

[0087] The characterization of DOP and CHS-DOP has been reported in the inventors' previous study (Tao S, Song Y, Ding S, et al. Dendrobium officinale polysaccharide-based carrier to enhance photodynamic immunotherapy. [J]. Carbohydrate polymers, 2023, 317:, 121089. DOI: 10.1016 / j.carbpol.2023.121089.). In short, the purity of DOP was 84.82%. DOP is composed of mannose and glucose in a ratio of 4.47:1 and has an average molecular weight of 80.32 kDa. The backbone of DOP is mainly [→4)-β-D-Manp-(1→4)-β-D-Glcp-(1→] n As for CHS-DOP, every seven monosaccharide units are modified by one CHS unit.

[0088] (2) Characterization of CHS-DOP and FA-DOP-CHS

[0089] FT-IR and 1 H NMR experiments were performed to verify whether the FA molecules were successfully grafted onto CHS-DOP. Figure 1 As shown in A, CHS-DOP and FA-DOP-CHS showed a -1 , 2900cm -1 and 1020cm -1 The broad absorption peaks at 1606 cm-1 and 1607 cm-2 are attributed to OH stretching vibration, CH stretching vibration and CO bending vibration. All of these are considered to be typical characteristics of polysaccharides. -1 and 1485cm -1 Two new characteristic peaks were found at , which can be attributed to the stretching vibration of the benzene ring skeleton of FA. These results indicate that FA successfully binds to CHS-DOP. 1 In the H NMR spectrum ( Figure 1 B) The characteristic peaks from δ0.5 ppm to δ2.5 ppm are the peaks of the methylene and methyl protons of CHS. The hydroxyl protons of DOP are located in the δ4.3-5.0 ppm region. The signals at δ6.65 and δ7.61 ppm (phenyl) are attributed to the aromatic protons of FA. The peak appearing at δ8.67 ppm is attributed to the piperidinyl protons of FA. These characteristic peaks of CHS and FA are also observed in the FA-DOP-CHS polymer.

[0090] (3) Critical micelle concentration (CMC)

[0091] The critical micelle concentration (CMC) results are as follows Figure 2 As shown in the figure, the CMC values ​​of CHS-DOP and FA-DOP-CHS in the medium were 1.28 and 1.12 μg / mL, respectively. These results indicate that CHS-DOP and FA-DOP-CHS can self-aggregate into micelles.

[0092] (4) Characterization of CHS@Dox NPs and FA@Dox NPs

[0093] The standard curve of doxorubicin was drawn ( Figure 3), and the concentration of doxorubicin encapsulated in CHS-DOP and FA-DOP-CHS (CHS@Dox and FA@Dox NPs) was determined based on the standard curve. The drug loading contents in CHS@Dox and FA@Dox NPs were 10.53% and 10.22%, respectively. The drug loading efficiencies were 63.20% and 61.31%, respectively. Dynamic light scattering (DLS) showed that the average diameters of CHS@Dox and FA@Dox NPs were 237.31±1.63nm and 212.53±2.49nm, respectively. Figure 1 C and Figure 4 ). The morphology of CHS@Dox and FA@Dox NPs was observed by transmission electron microscopy, confirming that they were spherical and had a relatively uniform size distribution. It is worth noting that the size of CHS@Dox or FA@Dox NPs observed by transmission electron microscopy was smaller than the hydrodynamic radius measured by dynamic light scattering. This may be because transmission electron microscopy measured the size of CHS@Dox or FA@DoxNPs in the dry state, while dynamic light scattering measured the size in the hydrated state. The zeta potential of CHS@Dox and FA@Dox NPs was -8.74±0.87mV and -12.8±0.17mV, respectively ( Figure 1 D). In addition, the particle size and PDI (polydispersity index) of CHS@Dox and FA@Dox NPs were monitored for 5 days and remained stable. ( Figure 5 and Figure 6 ).

[0094] like Figure 1 As shown in Figure E, the in vitro release profiles of doxorubicin from the nanoparticles were tested at pH 5.5 and 7.4. After 48 hours of incubation at pH 7.4, the cumulative release of doxorubicin from CHS@Dox and FA@Dox NPs was 41% and 55%, respectively. Compared with the neutral environment (pH 7.4), the acidic environment (pH 5.5) accelerated the release of doxorubicin, showing a cumulative release of approximately 60% and 72%, respectively, within 48 hours. This indicates that encapsulated doxorubicin is more readily released in the acidic tumor microenvironment.

[0095] Example 2 Cellular uptake studies

[0096] To investigate the uptake of Dox, CHS@Dox, or FA@Dox nanoparticles by 4T1 and CT-26 cells that overexpress folate receptor (FR) and L929 cells that lack FR, confocal laser scanning microscopy (CLSM, Nikon A1, Nikon Corporation, Tokyo, Japan) was used to observe the uptake of Dox, CHS@Dox, or FA@Dox nanoparticles. All cells were placed in confocal microscopy (1×10 cells per microscopy dish). 5Cells were cultured for 24 hours. Subsequently, the cells were treated with free Dox, CHS@Dox, or FA@Dox nanoparticles (5 μg / mL) for 8 hours, followed by DAPI staining for 10 minutes and observation under CLSM. To confirm the FR-mediated uptake of the nanoparticles, one group of cells was pretreated with free folic acid (FA, 20 μg / mL). To evaluate the FR-mediated uptake of FA@Dox nanoparticles, a subset of cells in each group was pretreated with free FA (20 μg / mL) and then treated with FA@Dox nanoparticles.

[0097] The results are as follows Figure 7 As shown, CHS@Dox or FA@Dox nanoparticles (red) localize to the perinuclear region of the cell lines, indicating that these nanoparticles are distributed in the perinuclear cytoplasm. The uptake efficiency of FA@Dox nanoparticles in cell lines expressing folate receptors (4T1 and CT-26) is significantly higher than that of CHS@Dox nanoparticles. This is not observed in the L929 cell line, which lacks folate receptors. Furthermore, the uptake of FA-targeted nanoparticles by 4T1 and CT-26 cell lines is significantly inhibited in the presence of excess free folate. This suggests that the uptake of targeted nanoparticles depends on folate receptor-mediated endocytosis. Furthermore, the role of folate receptors in the cellular uptake mechanism was further confirmed in L929 cells. The results showed that there was no significant difference in uptake in L929 cells with or without folate pretreatment. These experimental results demonstrate that FA-mediated FA@Dox nanoparticles have an active targeting effect on tumor cells with high cell surface expression of FR.

[0098] Example 3 Cytotoxicity Experiment

[0099] This example uses 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) for cytotoxicity experiments. Briefly, 4T1 or CT-26 cells were cultured at 1×10 4 Cells were cultured in 96-well plates at a density of 10 cells / well for 24 hours. The cells were then treated with free doxorubicin, CHS@Dox NPs, or FA@DoxNPs at different concentrations (0, 0.5, 1, 2, 4, 8 μg / mL) for another 48 hours. Subsequently, 20 μL of MTT solution (5 mg / mL) was added to each well for a 4-hour incubation. After aspirating the culture medium, the precipitated formazan crystals were dissolved in 100 μL of DMSO. Finally, the absorbance at 490 nm was measured using a microplate reader (Multiskan GO microplate spectrophotometer, Thermo Scientific, USA).

[0100] The half maximal inhibitory concentrations (IC50) of free Dox, CHS@Dox NPs, and FA@Dox NPs were calculated using GraphPad Prism software. 50 ). According to the IC of normal cells (L929) and tumor cells (4T1 or CT-26 cells) 50 The safety index of different formulations was calculated according to the following equation: Safety index = IC 50 (Normal cells) / IC 50 (tumor cells).

[0101] The survival rates of cancer cells (4T1 and CT-26 cells) and normal cells (L929 cells) after in vitro treatment with free Dox, CHS@Dox nanoparticles, and FA@Dox nanoparticles were evaluated by MTT assay. Figure 8 As shown in Table 1, the survival rates of 4T1, CT-26, and L929 cells treated with different dosing groups decreased with increasing Dox concentrations. CHS@Dox nanoparticles and FA@Dox nanoparticles exhibited concentration-dependent inhibitory effects on all three cell types, similar to free Dox. As shown in Table 1, the IC values ​​of CHS@Dox nanoparticles and FA@Dox nanoparticles against cancer cells (4T1 and CT-26 cells) were 50 Slightly higher than free Dox. A possible explanation is that Dox is slowly released from the drug-loaded nanoparticles, resulting in a lower concentration than free Dox under the same conditions. However, for the treatment of normal cells (L929 cells), the IC 50 The concentration of FA@Dox nanoparticles in the presence of free Dox is much higher than that in free Dox. Therefore, compared with free Dox, CHS@Dox nanoparticles and FA@Dox nanoparticles have a higher safety index.

[0102] Table 1 Median lethal dose (IC50) of free Dox, CHS@Dox NPs and FA@Dox NPs 50S ) and Safety index (SI)

[0103]

[0104] Example 4 Detection of Key Immunogenic Cell Death (ICD) Biomarkers

[0105] Assessment of key ICD biomarkers was performed as described in our previous study. Briefly, anti-calreticulin (CRT) and high-mobility group box 1 (HMGB1) expression was assessed by immunofluorescence and analyzed by confocal laser scanning microscopy. Extracellular ATP release was determined using an ATP detection kit.

[0106] CRT exposure, HMGB1 release, and ATP secretion assays were performed to investigate whether CHS@Dox and FA@Dox nanoparticles could trigger ICD. Figure 9 As shown in A, 4T1 and CT-26 cells treated with free Dox and CHS@Dox nanoparticles showed less cell surface CRT exposure (green), whereas significant cell surface CRT exposure was observed with FA@Dox nanoparticles, which was attributed to the FA-mediated targeting effect of FA@Dox nanoparticles. Figure 9 B and Figure 9 Figure C shows that the FA@Dox group significantly enhanced HMGB1 release and ATP secretion in 4T1 and CT-26 cells compared to the control group. Furthermore, more HMGB1 release and detectable ATP secretion were observed in the FA@Dox group compared to the free Dox and CHS@Dox groups. These results suggest that FA-targeted nanoparticles can enhance the release of damage-associated molecular patterns (DAMPs) during cancer cell therapy.

[0107] Example 5 In vivo anti-tumor and anti-metastasis effects

[0108] 1. Method

[0109] (1) In vivo biodistribution evaluation

[0110] First, CHS-DOP nanoparticles loaded with the dye DiR (CHS@DiR) and FA-DOP-CHS nanoparticles loaded with DiR (FA@DiR) were prepared using the same method as the nanoparticle preparation process of the present invention. To study the in vivo behavior of CHS@Dox nanoparticles and FA@Dox nanoparticles, BALB / c mice were inoculated with 4T1 breast tumors and divided into four groups of three mice each. When the tumor volume reached approximately 200 mm 3 Free DiR, CHS@DiR nanoparticles, and FA@DiR nanoparticles (5 mg / kg DiR dose) were injected via the tail vein. Fluorescence imaging was performed using a Xenogen IVIS-Spectrum system (USA) at 1, 3, 6, 12, and 24 hours after injection. At the end of the experiment, mice were sacrificed, and major organs (heart, liver, spleen, lung, and kidney) were harvested and imaged ex vivo using the same parameters.

[0111] (2) Anti-tumor effect in vivo

[0112] Female Balb / c mice (4-6 weeks old) were used to evaluate the antitumor and anti-metastatic effects of CHS@Dox and FA@Dox nanoparticles in vivo. For the 4T1 tumor growth model, a total of 5×10 6 4T1 cells were injected subcutaneously into the right hind leg area of ​​BALB / c mice. 3Mice (n = 6) were intravenously injected with PBS, free Dox, CHS@Dox, and FA@Dox nanoparticles at a dose of 5 mg / kg of Dox. Treatment was performed on day 0, day 3, and day 6 of the present invention. Tumor size was measured with an electronic caliper every 2 days, and tumor volume was calculated as volume = length × width. 2 ×0.5. On the 14th day after treatment, the mice were sacrificed, and the main organs (heart, liver, spleen, lung, kidney) and tumors were removed for blood and histological examinations. At the same time, the tumors were also stained with TUNEL immunofluorescence and Ki67 immunohistochemistry. The sections of H&E, TUNEL, and Ki67 were observed and imaged using an Olympus microscope (Olympus BX53, Japan). In addition, the collected blood samples were analyzed for blood biochemistry (including ALT, AST, BUN, UA, CK, and LDH) and blood routine (WBC, lymphocyte count, monocyte count, granulocyte count, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, PLT, and MPV).

[0113] (3) Anti-metastasis effect in vivo

[0114] For the 4T1 lung metastasis model, 4T1 cells (2×10 6 The 100 mg / kg sera (100 mg / kg) were injected into BALB / c mice via the tail vein. Subsequent treatments were performed as described above. Finally, the mice were sacrificed 14 days after treatment. The lungs of the mice were removed, examined for the number of metastatic nodules, and then sectioned and stained with H&E.

[0115] (4) Immune response analysis

[0116] To examine the treatment-induced CRT expression, HMGB1 release, and T lymphocyte infiltration in vivo, approximately 80 mm 3Mice bearing 4T1 tumors were intravenously (iv) injected with PBS, Dox, CHS@Dox nanoparticles, or FA@Dox nanoparticles every 3 days at a dose of 5 mg / kg each time. Tumors, inguinal lymph nodes (LNs), and spleens were harvested 3 days after the last treatment. Treatment-induced CRT expression and HMGB1 release at the tumor site were examined by immunofluorescence analysis. In addition, the removed tumors were cut into small pieces, and single-cell suspensions were prepared using the MACS Tumor Dissociation Kit (Miltenyi Biotec, Auburn, CA, 130-096-730) according to the protocol in the kit instructions. The cell suspensions were analyzed by flow cytometry after staining with anti-mouse CD3-FITC, anti-mouse CD4-PerCP-Cy5.5, anti-mouse CD8-PE-Cy7, anti-Perforinor-PE or anti-mouse CD4-PerCP-Cy5.5, anti-mouse CD25-BV421, and anti-mouse Foxp3-Alexa Fluor 647 antibodies. In addition, to examine DC maturation in vivo, DC maturation in lymph nodes and tumors was examined by flow cytometry after immunofluorescence staining using anti-mouse CD11c-PE, anti-mouse CD86-FITC, and anti-mouse CD80-APC antibodies. To analyze the secretion of cytokines induced by treatment, the concentrations of proinflammatory cytokines (including Granzyme B) in serum were analyzed using ELISA kits according to the manufacturer's instructions.

[0117] 2. Results

[0118] (1) Anti-tumor and anti-metastasis effects in vivo

[0119] The drug's in vivo distribution characteristics depend on the nanocarrier, not the drug itself. Fluorescence results showed that free DiR was primarily distributed in the liver, not in tumors. As expected, CHS@DiR and FA@DiR nanoparticles circulated, distributed, and selectively accumulated in tumors. Figure 10 Figure A shows that the fluorescence intensity of CHS@DiR nanoparticles and FA@DiR nanoparticles remained in the tumor for 24 hours. However, the fluorescence accumulation of FA@DiR nanoparticles in the tumor was faster and stronger than that of CHS@DiR nanoparticles, indicating that FA@DiR nanoparticles have advantages in tumor targeting. This result confirms the important role of FA in active targeting.

[0120] Subsequently, in vitro imaging results showed consistent targeting effects. CHS@DiR nanoparticles and FA@DiR nanoparticles were typically delivered to the liver and spleen and clearly retained in tumors, while free DiR did not have any tumor accumulation ability ( Figure 10B). Compared with CHS@DiR nanoparticles, FA@DiR nanoparticles accumulated more in lung tissue than in liver tissue, which may be related to the first-pass effect in the liver and the active targeting of FA, suggesting that FA@Dox nanoparticles may inhibit breast tumor metastasis to the lungs. Quantitative fluorescence results showed that the fluorescence intensity of FA@DiR nanoparticles in tumors and lungs was significantly stronger, which was significantly different from that of the free DiR group (p<0.001), confirming the good tumor accumulation effect of FA@DiR nanoparticles ( Figure 10 CD). Therefore, the designed FA-modified drug nanoparticles achieved significant targeting function in 4T1 tumor-bearing mice.

[0121] The present invention conducted an in vivo anti-tumor study on BALB / C mice bearing 4T1 tumors. The experimental method is as follows Figure 11 A. The anti-tumor effect in vivo is shown in Figure 11 As shown in BD, the results showed that compared with the model group, the tumor inhibition rate of free Dox was 58.71%, while the tumor inhibition rates of CHS@Dox and FA@Dox nanoparticles were 64.96% and 82.52%, respectively. The tumor inhibition rates of CHS@Dox and FA@Dox nanoparticles were 1.10 and 1.40 times that of free Dox, respectively. The results showed that compared with free Dox and CHS@Dox nanoparticles, FA@Dox nanoparticles had a better effect in limiting tumor growth in tumor-bearing mice, which should be attributed to the active targeting effect of FA. The body weight of each group increased steadily during the treatment period, indicating that the systemic toxicity of the therapeutic drug was low ( Figure 11 E). Figure 12 As shown, the FA@Dox nanoparticle group caused the most tumor cell death in H&E staining compared to the other groups. In addition, immunohistochemistry and immunofluorescence analysis showed that the tumor tissues in the FA@Dox nanoparticle group had the lowest Ki67 expression and the strongest TUNEL signal, suggesting that FA@Dox nanoparticles can inhibit tumor growth to the greatest extent.

[0122] In the in vivo anti-tumor experiment, after the mice were sacrificed and lung tissues were collected, tumor metastasis to lung tissue was observed ( Figure 13 According to the biodistribution of FA@DiR NPs ( Figure 10 B), we speculated that FA@DOP NPs could inhibit lung metastasis. Therefore, we established a lung metastasis model to verify the anti-metastatic effect of FA@Dox NPs. Figure 14 As shown in A, the experimental results are Figure 14 As shown in BD, the number of lung metastatic nodules in the FA@Dox group was significantly less than that in the other treatment groups ( Figure 14B). The average number of metastatic nodules per lung in the FA@Dox group (28±7) was much less than that in the control group (62±2), free Dox group (59±7) and CHS@Dox group (50±11) ( Figure 14 C). Meanwhile, the lung weight in the FA@Dox group was significantly less than that in the other groups ( Figure 14 D). In addition, the anti-tumor metastasis effect of FA@Dox was verified by images of the collected lungs and their sections. H&E staining further showed that the number and size of visible metastatic nodules in the FA@Dox group were significantly reduced ( Figure 14 EF). Overall, these results indicate that FA@Dox has remarkable efficacy in inhibiting not only breast tumor growth but also breast tumor lung metastasis.

[0123] (2) Immune response analysis

[0124] Calreticulin (CRT) exposure and high mobility group protein B1 (HMGB1) release are key indicators of ICD, promoting the maturation of dendritic cells (DCs) and subsequently triggering T lymphocyte-mediated anti-tumor immunity. In this study, we analyzed CRT exposure and HMGB1 release in tumor tissues. Figure 15 The results presented in the study showed that the doxorubicin (Dox) group could enhance the exposure of CRT and the release of HMGB1 to a certain extent, indicating that Dox could promote the infiltration of immune cells into tumors by inducing ICD. Further analysis showed that compared with the control group and the Dox group, the FA@Dox and CHS@Dox groups showed significantly enhanced CRT exposure and HMGB1 release, which should be attributed to the passive targeting effect of nanoparticles and the anti-tumor immune effect induced by DOP. We also analyzed the exposure of CRT and the release of HMGB1 in lung tissue. The results were consistent with the lung metastasis in Figure 10 The results were consistent with those observed in B. Subsequently, we performed immune cell analysis to confirm the initiation of adaptive immunity. We collected tumor tissues and tumor-draining lymph nodes (TDLNs) and performed flow cytometric analysis of mature DCs (CD11c + CD80 + CD86 + ). Figure 16 AB and Figure 17-18 As shown, the proportions of mature DCs in tumor tissues (23.38% ± 4.09%) and TDLNs (17.70% ± 0.82%) in the FA@Dox-treated group were significantly higher than those in the control and Dox-treated groups.

[0125] It has been reported that tumor cells undergoing ICD trigger a systemic immune response. Tumor-associated antigens (TAAs) released by dying tumor cells and damage-associated molecular patterns (DAMPs) released by ICD further stimulate the maturation of DCs and enhance lymphocyte infiltration, ultimately activating adaptive anti-tumor immune responses. Subsequently, the percentage of cytotoxic T lymphocytes in tumor tissues was analyzed using flow cytometry. The control group and the free Dox-treated group did not express CD4 and CD8, showing a lower immune response. However, the FA@Dox and CHS@Dox-treated groups showed higher levels of CD4 and CD8 expression, indicating effective activation of the anti-tumor immune response ( Figure 16 C. Figure 19 and Figure 20 AB). The FA@Dox-treated group showed higher levels of CD4 and CD8 expression than the CHS@Dox-treated group, which was attributed to the tumor targeting ability of FA. The same phenomenon was also observed in lung tissue with lung metastasis model ( Figure 21 ), indicating that FA@DOP nanoparticles targeted lung tissue and induced ICD effect.

[0126] It is well known that regulatory T cells (Treg, labeled by Foxp3) play an important role in preventing lymphocyte infiltration and inhibiting T cell activity. CD4 and CD25 play a key role in regulating the immune environment and activating T cells. Therefore, we further evaluated the expression of Treg cells (CD25 + Foxp3) ratio, and CD4 and Treg levels were detected in tumor sections using CD4 / Treg antibodies. Figure 16 D and Figure 22 As shown, compared with the control group and free Dox, the Treg cells (CD25 + Foxp3) ratio was significantly reduced. The reduction level in the FA@Dox treatment group was better than that in the CHS@Dox group. Figure 20 As shown in Figures BC, the CD4 / Treg ratio in the FA@Dox and CHS@Dox-treated groups showed a significant increase compared to the control and free Dox groups. Furthermore, the increase in the FA@Dox-treated group was superior to that in the CHS@Dox group, further demonstrating the effective activation of the immune response.

[0127] NK cells can recognize tumor cells and are not restricted by tumor neoantigens and major histocompatibility complex molecules. They are a supplement to T cell-based anti-tumor therapy. This paper evaluates the distribution of NK cells in the spleen and explores the NK cell proliferation ability of FA@Dox nanoparticles to explain the related immune response. Figure 16 E and Figure 23As shown in the results, CHS@Dox and FA@Dox treatment significantly promoted the content of NK cells in the spleen compared with the control group and free Dox group (p < 0.01). This indicates that nanoparticles can strongly stimulate and enhance the proliferation of NK cells for tumor immunotherapy.

[0128] In addition, as important cell markers for activating NK cells, perforin and granzyme B are important mediators of cell-mediated cytotoxic reactions. NK cells produce and secrete perforin and granzyme B to weaken and destroy tumor cells. Perforin is an important mediator of the effector function of granzyme B, which helps granzyme B enter target cells. After mice were treated with different drug groups, perforin was detected by flow cytometry and the secretion of granzyme B was detected by ELISA. Figure 16 FG and Figure 24 As shown, the results showed that the groups associated with CHS@Dox and FA@Dox nanoparticles showed significant enhancement of perforin expression and granzyme B release compared with the other groups (p < 0.01). Overall, these results indicate that CHS@Dox and FA@Dox can regulate the proliferation of NK cells, thereby enhancing their killing effect on tumor cells.

[0129] Example 6 In vivo and in vitro safety evaluation

[0130] The blood compatibility of CHS@Dox and FA@Dox nanoparticles was evaluated by hemolysis test at concentrations of 12.5-50 μg / mL. Figure 25 As shown in A, the hemolytic activity of CHS@Dox and FA@Dox nanoparticles was observed to be negligible. Figure 25 B showed a hemolysis rate of less than 5%, indicating good blood compatibility. In addition, histopathological analysis of normal tissues of mice was performed. As we all know, cardiotoxicity is one of the most serious side effects caused by Dox. Figure 26 and Figure 27 As shown, a large number of necrotic cardiomyocytes and myocardial fiber ruptures were observed in the free Dox group (black solid arrows in the heart sample). In contrast, no obvious necrosis was observed in the hearts of the CHS@Dox and FA@Dox nanoparticle groups. These results indicate that CHS@Dox and FA@Dox nanoparticles significantly reduced the cardiotoxicity of Dox. The significantly reduced toxicity of FA@Dox nanoparticles is likely attributed to the polysaccharide structure with high stability and ultra-sustained release. These characteristics of the drug carrier can reduce toxicity to normal tissues and prevent premature release of the drug during circulation.

[0131] To further investigate the safety of CHS@Dox and FA@Dox nanoparticles, blood biochemistry and routine blood analysis were performed. Figure 28As shown, the serum CK and LDH levels in the free Dox group were significantly increased compared with the control group, which was caused by the cardiotoxicity caused by Dox. However, no significant changes were observed in the CHS@Dox and FA@Dox nanoparticle groups, indicating that the nanoparticles significantly alleviated the cardiotoxicity caused by Dox. The results of routine blood analysis showed that white blood cells (WBC), lymphocytes (Lymph), neutrophils (Gran) and platelets (PLT) were significantly reduced due to Dox. These changes were significantly improved in the nanoparticle group (Table 2). These results are consistent with the above-mentioned histopathological analysis in the present invention. In short, FA@Dox nanoparticles are safe and reliable. Due to reduced toxicity and enhanced anti-tumor and anti-metastasis effects, FA@Dox nanoparticles have obvious advantages in cancer treatment. The schematic diagram of the FA@DOP nanoparticles of the present invention enhancing chemotherapy immunotherapy and inhibiting breast cancer growth and lung metastasis is shown in Figure 2. Figure 29 As stated.

[0132] Table 2 Blood routine analysis of mice after administration of free Dox, CHS@Dox nanoparticles, and FA@Dox nanoparticles

[0133]

[0134]

Claims

1. A nanoparticle for dual-targeted treatment of breast cancer, characterized in that: The anti-breast cancer chemotherapy drug is encapsulated by using a Dendrobium officinale polysaccharide-cholesterol hemisuccinate amphiphilic conjugate as a drug carrier, and the surface of the drug carrier is modified with a folic acid ligand; the structural formula of the Dendrobium officinale polysaccharide-cholesterol hemisuccinate amphiphilic conjugate is as follows: n is 1 to 2.

2. The nanoparticle according to claim 1, characterized in that: The nanoparticles have uniform sizes, a particle diameter of 210 to 220 nm, and a Zeta potential of -11 to -14 mV.

3. The nanoparticle according to claim 1, characterized in that: The anti-breast cancer chemotherapy drug is doxorubicin.

4. The nanoparticle according to claim 1, characterized in that: The Dendrobium officinale polysaccharide has a main chain of (1→4)-linked β-pyranose and β-D-pyranose glucose, and a side chain composed of terminal pyranose, and is composed of mannose and glucose in a ratio of 4.47:1, with an average molecular weight of 80..32 kDa.

5. The method for preparing nanoparticles for dual-targeted treatment of breast cancer according to any one of claims 1 to 4, characterized in that: The steps include: S1. reacting the Dendrobium officinale polysaccharide with cholesterol hemisuccinate under the action of 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride, so that the hydroxyl group of the Dendrobium officinale polysaccharide is connected to the carboxyl group of cholesterol hemisuccinate to form a Dendrobium officinale polysaccharide-cholesterol hemisuccinate amphiphilic conjugate; S2. The amphiphilic conjugate of Dendrobium officinale polysaccharide-cholesterol hemisuccinate prepared in step S1 is subjected to a connection reaction with folic acid in an organic solvent under the action of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 4-dimethylaminopyridine, and dialyzed and precipitated with alcohol to obtain a folic acid-conjugated Dendrobium officinale polysaccharide-cholesterol hemisuccinate conjugate; S3. dissolving the anti-breast cancer chemotherapy drug and the folic acid-conjugated Dendrobium officinale polysaccharide-cholesterol hemisuccinate conjugate described in step S2 in an organic solvent, reacting, dialyzing, centrifuging, and filtering to obtain nanoparticles encapsulating the anti-breast cancer chemotherapy drug.

6. The preparation method according to claim 5, characterized in that: The organic solvent in steps S2 and S3 is dimethyl sulfoxide.

7. The preparation method according to claim 5, characterized in that: The weight ratio of the anti-breast cancer chemotherapy drug to the folic acid-conjugated Dendrobium officinale polysaccharide-cholesterol hemisuccinate is 1:4-6.

8. Use of the nanoparticles for dual-targeted treatment of breast cancer according to any one of claims 1 to 4 in the preparation of a pharmaceutical preparation for treating breast cancer.

9. Use of the dual-targeted nanoparticles for treating breast cancer according to any one of claims 1 to 4 in the preparation of a drug for preventing and / or treating lung metastasis of breast cancer.

10. A pharmaceutical preparation for treating breast cancer, characterized in that: Nanoparticles for dual-targeted treatment of breast cancer comprising any one of claims 1 to 4.

Citation Information

Patent Citations

  • Tumor-targeted magnetic hydrogel nanoscale medicine delivery system and construction method and application thereof

    CN102228425A

  • Adriamycin co-drug-loading system and preparing method and application thereof

    CN105412939A

  • Preparation and application of phenylboronic acid / folic acid dual-targeting nano delivery carrier

    CN114748634A

  • Targeted nano preparation for treating cancer as well as preparation method and application thereof

    CN115581763A